Table 1 Patient demographics and clinical data before AGV implantation surgery
Patient | Age | Sex | Side | Diagnosis | Lens | Additional treatment |
|---|---|---|---|---|---|---|
1 | > 50 | F | R | NVG + PDR | Phakic | AC Lucentis |
2 | > 50 | F | L | NVG + PDR | Phakic | AC Lucentis |
3 | > 50 | M | R | NVG + PDR | Pseudophakic | AC Lucentis |
4 | 11–20 | M | L | SEC GL (PPV + silicon) + PVR | Pseudophakic | AC Avastin |
5 | 41–50 | M | R | SEC GL (PPV + silicon) + PDR | Pseudophakic | |
6 | > 50 | F | R | NVG + PDR | Pseudophakic | AC Avastin |
7 | > 50 | F | L | NVG + PDR | Pseudophakic/ Subluxated | AC Avastin |
8 | > 50 | M | R | PAOG/failed SLT | Pseudophakic/ Degen myopia | – |
9 | > 50 | M | R | PAOG | Phakic | – |
10 | > 50 | M | L | SEC GL (PPV + silicon) + PDR | Pseudophakic | – |
11 | 11–20 | F | L | SEC GL (CONG CAT/SEC IOL implant/opaque cornea) | Pseudophakic | – |
12 | 21–30 | M | R | SEC GL (PPV + silicon) | Phakic | – |
13 | 31–40 | F | L | CONG GL | Phakic/Bullous keratopathy | – |
14 | 41–50 | M | R | SEC GL (PPV + silicon) | Pseudophakic | – |
15 | > 50 | F | R | SEC GL (Keratoplasty) | Pseudophakic | – |
16 | 21–30 | M | L | SEC GL (PPV + Silicon) | Pseudophakic | – |
17 | 41–50 | F | L | Traumatic GL/Failed hydrus | Phakic/Bullous keratopathy | – |
18 | > 50 | F | R | Uveitic GL (HSV) | Phakic | – |
19 | > 50 | M | L | SEC GL (PPV + Silicon) + PDR | Phakic | AC Avastin |
20 | > 50 | M | L | SEC GL (anterior chamber IOL + bullous keratopathy) | Pseudophakic | – |
21 | 41–50 | M | L | SEC GL (PPV + silicon) + PDR | Pseudophakic | AC Avastin |
22 | > 50 | M | L | SEC GL (PPV + silicon) | Pseudophakic | – |
23 | 31–40 | M | L | CONG GL | Pseudophakic | – |
24 | 41–50 | M | R | POAG/RP | Pseudophakic | – |
25 | 41–50 | M | L | POAG/RP | Pseudophakic | – |
26 | > 50 | M | R | POAG/failed TRAB | Phakic | – |
27 | 21–30 | F | L | Traumatic+aphakic GL | Aphakic | – |